A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies

Status Recruiting

Clinical Trial Summary

The overall purpose of this study is to explore the therapeutic effect of LeY-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of myeloid malignancies.

Clinical Trial Description

Lewis -Y（LeY） is a difucosylated carbohydrate antigen and although its function is not known, it is expressed on a wide range of malignancies including myeloid malignancies. LeY-targeted CAR-T in myeloid malignancies had been explored and showed good efficiency in the treatment of myeloid malignancies. This trial is designed and conducted to test the safety and effectiveness of LeY-targeted CAR-T. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02958384
Study type	Interventional
Source	Southwest Hospital, China
Contact	Cheng Qian, MD, PhD
Phone	0086-023-68765461
Email	cqian3184@163.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	October 2016
Completion date	October 2020

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06383572` - Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies	Phase 1/Phase 2
Completed	`NCT01731951` - Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis	Phase 2
Recruiting	`NCT02958397` - A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies	Phase 1/Phase 2
Recruiting	`NCT05775406` - Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors	Phase 1
Recruiting	`NCT05807659` - Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies	Phase 2
Active, not recruiting	`NCT02452697` - Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT	Phase 2
Completed	`NCT04778410` - Study of Magrolimab Combinations in Participants With Myeloid Malignancies	Phase 2
Terminated	`NCT01366612` - PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation	Phase 3
Completed	`NCT03270748` - Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies	Phase 2
Recruiting	`NCT05115630` - Off-the-shelf NK Cells + SCT for Myeloid Malignancies	Phase 1/Phase 2
Recruiting	`NCT05796570` - A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies	Phase 2